Business Description
HealthCare Global Enterprises Ltd
ISIN : INE075I01017
Total Employee Number:
6,736Compare
Compare
Traded in other countries / regions
HCG.India IPO Date
2016-03-30Description
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.3 | |||||
Debt-to-EBITDA | 3.88 | |||||
Interest Coverage | 1.26 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.23 | |||||
Beneish M-Score | -2.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.9 | |||||
3-Year EBITDA Growth Rate | 13 | |||||
3-Year EPS without NRI Growth Rate | -5.1 | |||||
3-Year FCF Growth Rate | -23.2 | |||||
3-Year Book Growth Rate | 13.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 85.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.63 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.14 | |||||
9-Day RSI | 74.55 | |||||
14-Day RSI | 69.06 | |||||
3-1 Month Momentum % | 14.5 | |||||
6-1 Month Momentum % | -2.56 | |||||
12-1 Month Momentum % | 16.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.12 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.54 | |||||
Days Inventory | 17.09 | |||||
Days Sales Outstanding | 60.08 | |||||
Days Payable | 104.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | -5.05 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.1 | |||||
Operating Margin % | 8.73 | |||||
Net Margin % | 0.54 | |||||
EBITDA Margin % | 17.64 | |||||
FCF Margin % | 2.17 | |||||
OCF Margin % | 13.67 | |||||
ROE % | 1.3 | |||||
ROA % | 0.37 | |||||
ROIC % | 5.47 | |||||
3-Year ROIIC % | 8.58 | |||||
ROC (Joel Greenblatt) % | 10.01 | |||||
ROCE % | 7.68 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 711.24 | |||||
Forward PE Ratio | 77.25 | |||||
PE Ratio without NRI | 234.74 | |||||
Price-to-Owner-Earnings | 76.59 | |||||
PEG Ratio | 6.02 | |||||
PS Ratio | 3.82 | |||||
PB Ratio | 7.69 | |||||
Price-to-Tangible-Book | 11.24 | |||||
Price-to-Free-Cash-Flow | 178.87 | |||||
Price-to-Operating-Cash-Flow | 28.34 | |||||
EV-to-EBIT | 56.55 | |||||
EV-to-EBITDA | 25.71 | |||||
EV-to-Revenue | 4.53 | |||||
EV-to-FCF | 203.83 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Projected-FCF | 4.07 | |||||
Price-to-Median-PS-Value | 1.4 | |||||
Price-to-Peter-Lynch-Fair-Value | 9.39 | |||||
Price-to-Graham-Number | 10.83 | |||||
Earnings Yield (Greenblatt) % | 1.77 | |||||
FCF Yield % | 0.53 | |||||
Forward Rate of Return (Yacktman) % | 21.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HealthCare Global Enterprises Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 25,384.3 | ||
| EPS (TTM) (₹) | 0.965 | ||
| Beta | 0.3245 | ||
| 3-Year Sharpe Ratio | 0.8 | ||
| 3-Year Sortino Ratio | 1.44 | ||
| Volatility % | 32.71 | ||
| 14-Day RSI | 69.06 | ||
| 14-Day ATR (₹) | 20.585914 | ||
| 20-Day SMA (₹) | 633.335 | ||
| 12-1 Month Momentum % | 16.12 | ||
| 52-Week Range (₹) | 513.3 - 799.707184 | ||
| Shares Outstanding (Mil) | 149.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HealthCare Global Enterprises Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HealthCare Global Enterprises Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-13 | In 121 days | ||
| General meeting for 2026 | 2026-09-25 17:00 | In 73 days | ||
| Annual report for 2026 | 2026-09-03 | In 50 days | ||
| First quarter earnings conference call for 2027 | 2026-08-04 10:00 | In 21 days | ||
| First quarter earnings results for 2027 | 2026-08-04 | In 20 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-20 13:30 | 646.85 (+1.40%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-19 | 632.25 (-1.44%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-09 12:00 | 565.16 (-4.32%) | ||
| Third quarter earnings results for 2026 | 2026-02-05 | 605.51 (+1.64%) | ||
| INVESTOR & ANALYST MEET | 2025-12-04 16:00 | 714.19 (-0.70%) |
Show
Entries
HealthCare Global Enterprises Ltd Frequently Asked Questions
What is HealthCare Global Enterprises Ltd(NSE:HCG)'s stock price today?
The current price of NSE:HCG is ₹686.35. The 52 week high of NSE:HCG is ₹799.71 and 52 week low is ₹513.30.
When is next earnings date of HealthCare Global Enterprises Ltd(NSE:HCG)?
The next earnings date of HealthCare Global Enterprises Ltd(NSE:HCG) is 2026-08-04 Est..
Does HealthCare Global Enterprises Ltd(NSE:HCG) pay dividends? If so, how much?
HealthCare Global Enterprises Ltd(NSE:HCG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on HealthCare Global Enterprises Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers